Marshall Wace’s VanEck Biotech ETF BBH Stock Holding History

Marshall Wace’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2,350	Closed	-$388K	–	2432
2023 Q4	$388K	Buy	+2,350	New	+$362K	﹤0.01%	1803
2022 Q1	–	Sell	-1,029	Closed	-$194K	–	3350
2021 Q4	$194K	Buy	+1,029	New	+$198K	﹤0.01%	3165

Other funds holding BBH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MIM

Miller Investment Management West Conshohocken, Pennsylvania $1.01B AUM 13.96% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

CIG

Consolidated Investment Group Englewood, Colorado $922M AUM 28.87% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Marshall Wace's BBH Position: Q1 2024 in Review

Marshall Wace sold out of VanEck Biotech ETF (BBH) in Q1 2024, closing a stake of 2,350 shares — an estimated $388K sold.

Marshall Wace first reported a position in BBH in Q4 2021 and held it in 2 quarters. The position peaked at $388K in Q4 2023. 113 funds tracked by Wall St. Rank hold BBH as of Q1 2024.

Marshall Wace reported no remaining VanEck Biotech ETF position as of Q1 2024 after selling out during the quarter.
Marshall Wace sold 2,350 VanEck Biotech ETF shares in Q1 2024, an estimated $388K.
Marshall Wace first reported a position in VanEck Biotech ETF in Q4 2021 and held it in 2 quarters.
Marshall Wace's VanEck Biotech ETF position peaked at $388K in Q4 2023.
113 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q1 2024.

Based on Marshall Wace's 13F filing for Q1 2024, filed 15 May 2024.